1 . 8 6 ▁lit res ▁per ▁hour ▁with ▁a ▁wide ▁vari ability ▁of ▁ 4 4 % ▁between ▁individuals , ▁and ▁pl asma ▁half - life ▁is ▁ 9 . 5 ▁days . ▁ 6 2 % ▁of ▁i x az om ib ▁and ▁its ▁met abol ites ▁are ▁ex cret ed ▁via ▁the ▁ur ine ▁( of ▁which ▁less ▁than ▁ 3 . 5 % ▁in ▁un changed ▁form ) ▁and ▁ 2 2 % ▁via ▁the ▁fa ec es . ▁ ▁Chem istry ▁I x az om ib ▁is ▁a ▁bor onic ▁acid ▁and ▁pe pt ide ▁analog ue ▁like ▁the ▁older ▁bor te z om ib . ▁It ▁contains ▁a ▁derivative ▁ ▁of ▁the ▁am ino ▁acid ▁le uc ine ▁with ▁the ▁car box y lic ▁acid ▁group ▁being ▁replaced ▁by ▁a ▁bor onic ▁acid ; ▁and ▁the ▁remainder ▁of ▁the ▁mole c ule ▁has ▁been ▁li ken ed ▁to ▁phen yl al an ine . ▁The ▁structure ▁has ▁been ▁found ▁through ▁a ▁large - scale ▁screen ing ▁of ▁bor on - cont aining ▁mole cules . ▁ ▁History ▁The ▁drug ▁was ▁developed ▁by ▁Tak eda . ▁It ▁got ▁US ▁and ▁European ▁or phan ▁drug ▁status ▁for ▁multiple ▁my el oma ▁in ▁ 2 0 1 1 , ▁and ▁for ▁AL ▁am y lo idos is ▁in ▁ 2 0 1 2 . ▁Tak eda ▁submitted ▁a ▁US ▁new ▁drug ▁application ▁for ▁multiple ▁my el oma ▁in ▁July ▁ 2 0 1 5 . ▁In ▁September ▁ 2 0